Stocks · News reference

Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

Sep 1, 2026, 1:32 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 1, 2026, 10:12 AMBenzinga Newsdesk
IDEAYA Sets November R&D Day To Share New Pancreatic Cancer Research And Strategy
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and
IDYA
BenzingaAug 31, 2026, 10:05 AMBenzinga Newsdesk
IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026
IDYA
BenzingaAug 19, 2026, 10:03 AMBenzinga Newsdesk
IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma
Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor,
IDYA RHHBY